Colorectal cancer in patients with inflammatory bowel disease.
Patients with inflammatory bowel disease (IBD) are subject to increased risks for the development of colorectal cancer (CRC), risks that are attributed to the duration and anatomic extent of disease in patients with ulcerative colitis and Crohn's disease. Although IBD contributes only 1%-2% to all cases of CRC, the mortality rate in patients with a diagnosis of CRC in the setting of IBD is higher than for those afflicted with sporadic cases of CRC. Given the length of time from IBD onset to the development of CRC, surveillance continues to be widely practiced. Although still under development, novel techniques for the earlier detection of dysplastic lesions have moved to the forefront in an attempt to optimize surveillance strategies and decrease the risk of CRC development.
Vagefi
Parsia A
PA
Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA.
Longo
Walter E
WE
D014408:Biomarkers, Tumor; D002471:Cell Transformation, Neoplastic; D002908:Chronic Disease; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D009154:Mutation; D015995:Prevalence; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor